Cargando…
Novel Allosteric Mechanism of Dual p53/MDM2 and p53/MDM4 Inhibition by a Small Molecule
Restoration of the p53 tumor suppressor for personalised cancer therapy is a promising treatment strategy. However, several high-affinity MDM2 inhibitors have shown substantial side effects in clinical trials. Thus, elucidation of the molecular mechanisms of action of p53 reactivating molecules with...
Autores principales: | Grinkevich, Vera V., Vema, Aparna, Fawkner, Karin, Issaeva, Natalia, Andreotti, Virginia, Dickinson, Eleanor R., Hedström, Elisabeth, Spinnler, Clemens, Inga, Alberto, Larsson, Lars-Gunnar, Karlén, Anders, Wilhelm, Margareta, Barran, Perdita E., Okorokov, Andrei L., Selivanova, Galina, Zawacka-Pankau, Joanna E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9198586/ https://www.ncbi.nlm.nih.gov/pubmed/35720128 http://dx.doi.org/10.3389/fmolb.2022.823195 |
Ejemplares similares
-
The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors
por: Dickinson, Eleanor R., et al.
Publicado: (2015) -
The p53/MDM2/MDMX-targeted therapies—a clinical synopsis
por: Jiang, Liren, et al.
Publicado: (2020) -
Protoporphyrin IX is a dual inhibitor of p53/MDM2 and p53/MDM4 interactions and induces apoptosis in B-cell chronic lymphocytic leukemia cells
por: Jiang, Liren, et al.
Publicado: (2019) -
ROS-dependent activation of JNK converts p53 into an efficient inhibitor of oncogenes leading to robust apoptosis
por: Shi, Y, et al.
Publicado: (2014) -
Energetic Landscape of MDM2-p53 Interactions by Computational Mutagenesis of the MDM2-p53 Interaction
por: Thayer, Kelly M., et al.
Publicado: (2016)